Acurx Pharmaceuticals, Inc. (ACXP) company profile

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a novel class of small-molecule antibiotics to treat serious bacterial infections. Its development pipeline centers on antibiotic candidates that employ a Gram-positive selective spectrum approach to inhibit the bacterial enzyme DNA polymerase IIIC, which stops DNA replication and leads to cell death. The company's lead product candidate, ibezapolstat, targets Clostridioides difficile infections, while its earlier-stage candidate, ACX-375C, is being developed to address other resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

The company conducts drug development activities, preclinical evaluations, and clinical trials across multiple jurisdictions where it maintains patents, including the United States, the European Union, Japan, and Canada. It also collaborates with academic institutions on scientific research, including Leiden University Medical Center in the Netherlands and the University of Houston in Texas. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Acurx Pharmaceuticals's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 12, 2026, we had four full-time employees.”